Steve Kafka

Background

Steve Kafka PhD is a General Partner at S32 focused on precision medicine technologies leveraging data, AI, and emerging biology. He previously served as founding CEO and Executive Chairman of Thrive Earlier Detection (acquired by Exact Sciences) and Executive Chairman at ArcherDX (acquired by Invitae). He held leadership roles at Foundation Medicine (acquired by Roche) and specializes in multi-cancer early detection and computational biology. He holds a PhD in Political Economy from Harvard and a BA in Economics and Political Science from Stanford.

Investment Focus

Notable Investments

BigHat Biosciences

AI-driven antibody drug design

Manifold Bio

Protein expression library platform

Exai Bio

RNA-based multi-cancer detection